REVENUE (Tables)

12 Months Ended

Oct. 31, 2023

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Year Ended October 31, 2023:
Americas	$	1,099	$	634	$	999	$	2,732
Europe	851		417		486		1,754
Asia Pacific	1,560		517		270		2,347
Total	$	3,510	$	1,568	$	1,755	$	6,833

Year Ended October 31, 2022:
Americas	$	1,109	$	567	$	1,006	$	2,682
Europe	844		382		473		1,699
Asia Pacific	1,677		503		287		2,467
Total	$	3,630	$	1,452	$	1,766	$	6,848

Year Ended October 31, 2021:
Americas	$	953	$	510	$	941	$	2,404
Europe	842		378		468		1,688
Asia Pacific	1,509		472		246		2,227
Total	$	3,304	$	1,360	$	1,655	$	6,319

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


		Years Ended October 31,
		2023		2022		2021
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical		$	2,433	2,515		$	2,224
Chemicals and Advanced Materials		1,543		1,521		1,328
Diagnostics and Clinical		966		963		938
Food		628		617		601
Academia and Government		601		576		576
Environmental and Forensics		662		656		652
Total		$	6,833	$	6,848	$	6,319

Revenue by Type
Instrumentation		$	2,742	2,907		$	2,657
Non-instrumentation and other		4,091		3,941		3,662
Total		$	6,833	$	6,848	$	6,319

Contract with Customer, Asset and Liability

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2022 and 2023:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2021	$	519

Net revenue deferred in the period	437
Revenue recognized that was included in the contract liability balance at the beginning of the period	(372)
Change in deferrals from customer cash advances, net of revenue recognized	11

Currency translation and other adjustments	(38)
Ending balance as of October 31, 2022	$	557
Net revenue deferred in the period	488
Revenue recognized that was included in the contract liability balance at the beginning of the period	(409)
Change in deferrals from customer cash advances, net of revenue recognized	(28)

Currency translation and other adjustments	8
Ending balance as of October 31, 2023	$	616